{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:27:22Z","timestamp":1717050442237},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41440-018-0011-y","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T03:44:13Z","timestamp":1518493453000},"page":"234-245","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Innovative lipid-based carriers containing cationic derivatives of polyisoprenoid alcohols augment the antihypertensive effectiveness of candesartan in spontaneously hypertensive rats"],"prefix":"10.1038","volume":"41","author":[{"given":"Olga","family":"Gawry\u015b","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Baranowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Gawarecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"\u015awie\u017cewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Dyniewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof H","family":"Olszy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Masnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Chmielewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Kompanowska-Jezierska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbrc.2011.03.059","volume":"407","author":"L Surmacz","year":"2011","unstructured":"Surmacz L, Swiezewska E. Polyisoprenoids\u2014secondary metabolites or physiologically important superlipids? Biochem Biophys Res Commun. 2011;407:627\u201332. https:\/\/doi.org\/10.1016\/j.bbrc.2011.03.059","journal-title":"Biochem Biophys Res Commun."},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.plipres.2005.05.002","volume":"44","author":"E Swiezewska","year":"2005","unstructured":"Swiezewska E, Danikiewicz W. Polyisoprenoids: structure, biosynthesis and function. Prog Lipid Res. 2005;44:235\u201358. https:\/\/doi.org\/10.1016\/j.plipres.2005.05.002","journal-title":"Prog Lipid Res."},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/S0021-9258(18)89424-8","volume":"260","author":"C Valtersson","year":"1985","unstructured":"Valtersson C, van Duyn G, Verkleij AJ, Chojnacki T, de Kruijff B, Dallner G. The influence of dolichol, dolichol esters, and dolichyl phosphate on phospholipid polymorphism and fluidity in model membranes. J Biol Chem. 1985;260:2742\u201351.","journal-title":"J Biol Chem."},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.abb.2011.10.018","volume":"517","author":"MD Hartley","year":"2012","unstructured":"Hartley MD, Imperiali B. At the membrane frontier: a prospectus on the remarkable evolutionary conservation of polyprenols and polyprenyl-phosphates. Arch Biochem Biophys. 2012;517:83\u201397. https:\/\/doi.org\/10.1016\/j.abb.2011.10.018","journal-title":"Arch Biochem Biophys."},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.18388\/abp.2007_3191","volume":"54","author":"Z Madeja","year":"2007","unstructured":"Madeja Z, Rak M, Wybieralska E, R\u00f3za\u0144ski I, Masnyk M, Chmielewski M, \u0141ysek R, Chojnacki T, Jankowski W, Ciepichal E, Swiezewska E, Tekle M, Dallner G. New cationic polyprenyl derivative proposed as a lipofecting agent. Acta Biochim Pol. 2007;54:873\u20136.","journal-title":"Acta Biochim Pol."},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/bmj.316.7140.1295","volume":"316","author":"M Pirmohamed","year":"1998","unstructured":"Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ Br Med J. 1998;316:1295\u20138.","journal-title":"BMJ Br Med J."},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818\u201322. https:\/\/doi.org\/10.1126\/science.1095833","journal-title":"Science."},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/hr.2015.54","volume":"38","author":"K Shimamoto","year":"2015","unstructured":"Shimamoto K, Kimoto M, Matsuda Y, Asano K, Kajikawa M. Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. Hypertens Res. 2015;38:695\u2013700. https:\/\/doi.org\/10.1038\/hr.2015.54","journal-title":"Hypertens Res."},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ejlt.201300489","volume":"116","author":"O Gawrys","year":"2014","unstructured":"Gawrys O, Olszynski KH, Gawarecka K, Swiezewska E, Chojnacki T, Masnyk M, Chmielewski M, Kompanowska-Jezierska E. Cationic derivative of polyprenol, a potential component of liposomal drug carriers, does not alter renal function in rats. Eur J Lipid Sci Technol. 2014;116:659\u201362. https:\/\/doi.org\/10.1002\/ejlt.201300489","journal-title":"Eur J Lipid Sci Technol."},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.pharep.2013.09.009","volume":"66","author":"O Gawrys","year":"2014","unstructured":"Gawrys O, Polkowska M, Roszkowska-Chojecka M, Gawarecka K, Chojnacki T, Swiezewska E, Masnyk M, Chmielewski M, Rafa\u0142owska J, Kompanowska-Jezierska E. Effects of liposomes with polyisoprenoids, potential drug carriers, on the cardiovascular and excretory system in rats. Pharmacol Rep. 2014;66:273\u20138. https:\/\/doi.org\/10.1016\/j.pharep.2013.09.009","journal-title":"Pharmacol Rep."},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003088-200241010-00002","volume":"41","author":"CH Gleiter","year":"2002","unstructured":"Gleiter CH, M\u00f6rike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002;41:7\u201317. https:\/\/doi.org\/10.2165\/00003088-200241010-00002","journal-title":"Clin Pharmacokinet."},{"key":"11_CR12","first-page":"1227","volume":"3","author":"MP Puranik","year":"2012","unstructured":"Puranik MP, Wadher SJ, Kosarkar AL, Yeole PG. Method development and validation of candesartan cilexetil by RP-HPLC. Int J Res Pharm Biomed Sci. 2012;3:1227\u201330.","journal-title":"Int J Res Pharm Biomed Sci."},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/hr.2015.142","volume":"39","author":"RC Hermida","year":"2016","unstructured":"Hermida RC, Ayala DE, Smolensky MH, Fern\u00e1ndez JR, Moj\u00f3n A, Portaluppi F. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res. 2016;39:277\u201392. https:\/\/doi.org\/10.1038\/hr.2015.142","journal-title":"Hypertens Res"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1748-1716.2010.02222.x","volume":"201","author":"M Kuczeriszka","year":"2011","unstructured":"Kuczeriszka M, Olszy\u0144ski KH, G\u0105siorowska A, Sadowski J, Kompanowska-Jezierska E. Interaction of nitric oxide and the cytochrome P-450 system on blood pressure and renal function in the rat: dependence on sodium intake. Acta Physiol. 2011;201:493\u2013502. https:\/\/doi.org\/10.1111\/j.1748-1716.2010.02222.x","journal-title":"Acta Physiol."},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.ki.5000338","volume":"69","author":"B Badzy\u0144ska","year":"2006","unstructured":"Badzy\u0144ska B, Sadowski J. Renal hemodynamic responses to intrarenal infusion of acetylcholine: comparison with effects of PGE2 and NO donor. Kidney Int. 2006;69:1774\u20139. https:\/\/doi.org\/10.1038\/sj.ki.5000338","journal-title":"Kidney Int."},{"key":"11_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0731-7085(01)00643-4","volume":"28","author":"TD Nolin","year":"2002","unstructured":"Nolin TD, Colaizzi IV, Palevsky PM, Matzke GR, Frye RF. Rapid microtiter plate assay for determination of inulin in human plasma and dialysate. J Pharm Biomed Anal. 2002;28:209\u201315. https:\/\/doi.org\/10.1016\/S0731-7085(01)00643-4","journal-title":"J Pharm Biomed Anal."},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1097\/01.ASN.0000128219.65330.EA","volume":"15","author":"C Maric","year":"2004","unstructured":"Maric C, Sandberg K, Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol. 2004;15:1546\u201356. https:\/\/doi.org\/10.1097\/01.ASN.0000128219.65330.EA","journal-title":"J Am Soc Nephrol."},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1046\/j.1523-1755.2002.00516.x","volume":"62","author":"XJ Zhou","year":"2002","unstructured":"Zhou XJ, Vaziri ND, Zhang J, Wang HW, Wang XQ. Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade. Kidney Int. 2002;62:914\u201321. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00516.x","journal-title":"Kidney Int."},{"key":"11_CR19","first-page":"181","volume":"2","author":"JM Neutel","year":"2000","unstructured":"Neutel JM, Weir MR, Moser M, Harris S, Edwards D, Michelson EL, Wang R, Investigators AS. The effects of candesartan cilexetil in isolated systolic hypertension: a clinical experience trial. J Clin Hypertens. 2000;2:181\u20136.","journal-title":"J Clin Hypertens."},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijcard.2016.04.007","volume":"214","author":"Z Wang","year":"2016","unstructured":"Wang Z, Niu Q, Peng X, Li M, Liu K, Liu Y, Liu J, Jin F, Li X, Wei Y. Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR. Int J Cardiol. 2016;214:348\u201357. https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.007","journal-title":"Int J Cardiol."},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"e12274","DOI":"10.14814\/phy2.12274","volume":"3","author":"SC Choisy","year":"2015","unstructured":"Choisy SC, Kim S-J, Hancox JC, Jones SA, James AF. Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats. Physiol Rep. 2015;3:e12274. https:\/\/doi.org\/10.14814\/phy2.12274","journal-title":"Physiol Rep."},{"key":"11_CR22","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1177\/14703203010020011601","volume":"2","author":"K Skov","year":"2001","unstructured":"Skov K, Mogensen S, Mulvany MJ. Persistent effect of treatment with candesartan cilexetil on blood pressure in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2001;2:S91\u20134. https:\/\/doi.org\/10.1177\/14703203010020011601","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1161\/01.STR.31.10.2478","volume":"31","author":"Y Nishimura","year":"2000","unstructured":"Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31:2478\u201386. https:\/\/doi.org\/10.1161\/01.STR.31.10.2478","journal-title":"Stroke"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s003950050221","volume":"93","author":"Y Nishimura","year":"1998","unstructured":"Nishimura Y, Xu T, J\u00f6hren O, H\u00e4user W, Saavedra JM. The angiotensin AT1 receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1 receptor expression. Basic Res Cardiol. 1998;93:63\u201368. Suppl 2","journal-title":"Basic Res Cardiol."},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/sj.ki.5001988","volume":"71","author":"A Keppler","year":"2007","unstructured":"Keppler A, Gretz N, Schmidt R, Kloetzer H-M, Groene H-J, Lelongt B, Meyer M, Sadick M, Pill J. Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int. 2007;71:74\u20138. https:\/\/doi.org\/10.1038\/sj.ki.5001988","journal-title":"Kidney Int."},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5527\/wjn.v4.i1.57","volume":"4","author":"S Lopez-Giacoman","year":"2015","unstructured":"Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol. 2015;4:57\u201373. https:\/\/doi.org\/10.5527\/wjn.v4.i1.57","journal-title":"World J Nephrol."},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"14645","DOI":"10.1074\/jbc.M710202200","volume":"283","author":"M Bentinger","year":"2008","unstructured":"Bentinger M, Tekle M, Brismar K, Chojnacki T, Swiezewska E, Dallner G. Polyisoprenoid epoxides stimulate the biosynthesis of coenzyme Q and inhibit cholesterol synthesis. J Biol Chem. 2008;283:14645\u201353. https:\/\/doi.org\/10.1074\/jbc.M710202200","journal-title":"J Biol Chem."},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/JAD-2004-6204","volume":"6","author":"E Bergamini","year":"2004","unstructured":"Bergamini E, Bizzarri R, Cavallini G, Cerbai B, Chiellini E, Donati a GoriZ, Manfrini a, Parentini I, Signori F, Tamburini I. Ageing and oxidative stress: a role for dolichol in the antioxidant machinery of cell membranes? J Alzheimers Dis. 2004;6:129\u201335.","journal-title":"J Alzheimers Dis."},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/bcp.12282","volume":"77","author":"L Meer Van","year":"2014","unstructured":"Van Meer L, Moerland M, Cohen AF, Burggraaf J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol. 2014;77:947\u201357. https:\/\/doi.org\/10.1111\/bcp.12282","journal-title":"Br J Clin Pharmacol."},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0192623309332992","volume":"37","author":"KJ Boudonck","year":"2009","unstructured":"Boudonck KJ, Mitchell MW, N\u00e9met L, Keresztes L, Nyska A, Shinar D, Rosenstock M. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009;37:280\u201392. https:\/\/doi.org\/10.1177\/0192623309332992","journal-title":"Toxicol Pathol."},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1152\/physiolgenomics.00150.2005","volume":"25","author":"MR Garrett","year":"2006","unstructured":"Garrett MR, Joe B, Yerga-Woolwine S. Genetic linkage of urinary albumin excretion in Dahl salt-sensitive rats: influence of dietary salt and confirmation using congenic strains. Physiol Genom. 2006;25:39\u201349. https:\/\/doi.org\/10.1152\/physiolgenomics.00150.2005","journal-title":"Physiol Genom."},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/01.HYP.16.5.544","volume":"16","author":"LG Feld","year":"1990","unstructured":"Feld LG, Cachero S, Van Liew JB., Zamlauski-Tucker M, Marianna Noble B Enalapril and renal injury in spontaneously hypertensive rats. Hypertension. 1990;16:544\u201354. https:\/\/doi.org\/10.1161\/01.HYP.16.5.544","journal-title":"Hypertension."},{"key":"11_CR33","first-page":"207","volume":"25","author":"K Komatsu","year":"1995","unstructured":"Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW. Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Eff angiotensin-Convert Enzym Inhib Hypertens. 1995;25:207\u2013213.","journal-title":"Eff angiotensin-Convert Enzym Inhib Hypertens."},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"F216","DOI":"10.1152\/ajprenal.00255.2012","volume":"305","author":"BH Inoue","year":"2013","unstructured":"Inoue BH, Arruda-Junior DF, Campos LC, Barreto ALT, Rodrigues MV, Krieger JE, Girardi ACC. Progression of microalbuminuria in SHR is associated with lower expression of critical components of the apical endocytic machinery in the renal proximal tubule. Am J Physiol Ren Physiol. 2013;305:F216\u201326. https:\/\/doi.org\/10.1152\/ajprenal.00255.2012","journal-title":"Am J Physiol Ren Physiol."},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/01.HYP.30.3.677","volume":"30","author":"JF Reckelhoff","year":"1997","unstructured":"Reckelhoff JF, Zhang H, Granger JP. Decline in renal hemodynamic function in aging SHR: role of androgens. Hypertension. 1997;30:677\u201381. https:\/\/doi.org\/10.1161\/01.HYP.30.3.677","journal-title":"Hypertension."},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/00004872-199412000-00009","volume":"12","author":"K Skov","year":"1994","unstructured":"Skov K, Nyengaard JR, Korsgaard N, Mulvany MJ. Number and size of renal glomeruli in spontaneously hypertensive rats. J Hypertens. 1994;12:1373\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7706696","journal-title":"J Hypertens."},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/HJH.0b013e3282f29876","volume":"26","author":"RJ Johnson","year":"2008","unstructured":"Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens. 2008;26:381\u2013391. https:\/\/doi.org\/10.1097\/HJH.0b013e3282f29876","journal-title":"J Hypertens."},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"F191","DOI":"10.1152\/ajprenal.0197.2001","volume":"282","author":"B Rodr\u00edguez-Iturbe","year":"2002","unstructured":"Rodr\u00edguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Ch\u00e1vez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Ren Physiol. 2002;282:F191\u2013201. https:\/\/doi.org\/10.1152\/ajprenal.0197.2001","journal-title":"Am J Physiol Ren Physiol."},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261\u20138. https:\/\/doi.org\/10.1007\/978-3-642-00477-3_13","journal-title":"Nat Biotechnol."},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1089\/bar.2012.9960","volume":"1","author":"LR Martin","year":"2005","unstructured":"Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189\u201399. https:\/\/doi.org\/10.1089\/bar.2012.9960","journal-title":"Ther Clin Risk Manag."},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"e0153633","DOI":"10.1371\/journal.pone.0153633","volume":"11","author":"E Grecka","year":"2016","unstructured":"Grecka E, Statkiewicz M, Gorska A, Biernacka M, Grygorowicz MA, Masnyk M, Chmielewski M, Gawarecka K, Chojnacki T, Swiezewska E, Malecki M. Prenyl ammonium salts\u2014new carriers for gene delivery: a B16-F10 mouse melanoma model. PLoS ONE. 2016;11:e0153633 https:\/\/doi.org\/10.1371\/journal.pone.0153633","journal-title":"PLoS ONE."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0011-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0011-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:35Z","timestamp":1684617515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0011-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0011-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"21 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}